Eight weeks on Mounjaro — what's actually happening by now

You've just crossed from the first pen into the second. Here's what that actually means.

The first Mounjaro pen (four weekly 2.5 mg doses) isn't designed to produce dramatic weight loss. Its job is to let your system adjust to a new class of medicine before the dose climbs. So if weeks one to four felt underwhelming on the scales, that's expected. The early weeks on Mounjaro are mostly about tolerability, not transformation.

Week five is where things typically shift. A prescriber who is satisfied with how you handled the starter dose will usually move you to 5 mg, and that's often when appetite suppression becomes noticeably stronger. By week eight you're two to three weeks into that higher dose, which is a more meaningful signal. Some people feel fuller after a few bites of a meal. Others notice they've stopped thinking about food between meals in the way they used to. Both are normal, and neither is the whole story.

Weight loss at this stage varies considerably between individuals. Some people see a clear downward trend by week eight. Others find the scale has barely moved, even with real changes in appetite, factors like fluid retention, the composition of what's lost (fat versus muscle mass), and how recently a dose increased all play a role. The tirzepatide overview explains how the dual GIP and GLP-1 mechanism works across time, which gives useful context for why the early weeks often look different to later ones in clinical trials.

One practical check worth doing now: weigh yourself at the same time of day, wearing the same amount of clothing, on the same scale. A single morning reading tells you less than a consistent weekly record does.

Side effects at week eight, what's likely settling, and what still needs attention

The most common side effects with Mounjaro are gastrointestinal: nausea, indigestion, belching, loose stools, constipation. They follow a predictable arc, peaking in the days after a dose increase, then gradually easing over one to two weeks as the body adapts. If you stepped up to 5 mg at week five, week eight puts you past that adjustment window. Many people find GI symptoms that felt significant at weeks five and six are much quieter by now.

That said, 'quieter' isn't the same as 'gone'. Some people carry a mild background nausea for longer, particularly if they eat large meals or high-fat foods. Eating slowly, keeping portions moderate and staying well hydrated are the practical levers, advice your prescriber or the patient information leaflet will reinforce. The six-week point covers the dose-increase adjustment in more detail if that period is still fresh for you.

Two things that should not be dismissed as normal adjustment: severe or persistent stomach pain, particularly if it spreads to your back. The MHRA's Yellow Card scheme exists precisely for suspected side effects, including any reaction you're unsure about. Acute pancreatitis is a known but uncommon risk with GLP-1 medicines; if the pain is severe, get medical help rather than waiting to see if it passes.

Injection-site reactions (mild redness, itching, a small lump) are also common early on. Rotating between the abdomen, thigh and upper arm each week, and allowing at least a few centimetres between injection spots, keeps this manageable for most people.

What your prescriber is looking for at this stage, and why clinical re-review matters

A Mounjaro repeat isn't automatic. Before a new supply is approved, a clinician looks at how the previous period went: how much weight has shifted, how well the dose was tolerated, and whether any concerns have come up. Eight weeks of data gives a prescriber a real baseline to work from. It's not just a box-ticking exercise, the clinical oversight at nume reflects the view that these conversations are where treatment actually gets personalised.

At week eight, the relevant questions are usually: is 5 mg well tolerated? Is there early weight movement? Are there any symptoms that should change the plan? If the dose is going well, the next step in the titration schedule may be on the horizon. If the first pen produced side effects that persisted, a prescriber might recommend spending longer at 2.5 mg before moving up. Both are valid clinical paths, there's no single right answer that applies to everyone.

For context on the longer picture, the Mounjaro pillar page covers the full titration schedule and what the SURMOUNT-1 trial showed across 72 weeks, useful reading once you've got a few weeks under your belt and want to understand where the dose escalation is heading.

Questions about the cost of continuing treatment are reasonable at this point too. The Mounjaro price comparison guide lays out what the UK market looks like and what a legitimate private prescription includes. Worth knowing before you renew anywhere.

What week eight isn't, and what comes next

Eight weeks is not a verdict. The clinical trials for Mounjaro ran to 72 weeks, and the clearest weight-loss results accumulated well beyond the early months. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants at 15 mg saw an average body-weight reduction of around 20–21% over 72 weeks. Week eight is somewhere in the first chapter of that story, not the final page.

That doesn't mean early results don't matter. A prescriber paying attention at week eight can spot patterns that inform the next decision, dose, timing, what support is helpful alongside the medicine. The four-week mark page and the three-week page each trace earlier parts of that trajectory if you want to compare notes on your own experience so far.

If you're wondering whether this is working for you, or you're thinking about starting and want to understand what the first eight weeks typically look like, talking to a prescriber is the right next step. Treatment involves more than a pen and a dose schedule, and the right clinical oversight makes a measurable difference to how it goes. You can start your free consultation with our GPhC-registered prescribers to see whether Mounjaro is appropriate for you.